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cular disease (CVD) risks, N6,N6,N6-trimethyl-L-lysine (trimethyllysine, TML). Stable-isotope-dilution
tandem mass spectrometry analyses of an independent validation cohort (N = 2,140) confirmed TML lev-
els are independently associated with incident (3-year) major adverse cardiovascular event risks (hazards
ratio [HR], 2.4; 95% CI, 1.7-3.4) and incident (5-year) mortality risk (HR, 2.9; 95% CI, 2.0-4.2). Genome-
wide association studies identified several suggestive loci for TML levels, but none reached genome-wide
significance; and d9(trimethyl)-TML isotope tracer studies confirmed TML can serve as a nutrient pre-
cursor for gut microbiota-dependent generation of trimethylamine (TMA) and the atherogenic metabolite
trimethylamine N-oxide (TMAO). Although TML was shown to be abundant in both plant- and animal-
derived foods, mouse and human fecal cultures (omnivores and vegans) showed slow conversion of TML
to TMA. Furthermore, unlike chronic dietary choline, TML supplementation in mice failed to elevate
plasma TMAO or heighten thrombosis potential in vivo. Thus, TML is identified as a strong predictor
of incident CVD risks in subjects and to serve as a dietary precursor for gut microbiota-dependent gen-
eration of TMAO; however, TML does not appear to be a major microbial source for TMAO generation
in vivo.
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Introduction
Untargeted metabolomics analyses of  biological samples hold promise as a discovery platform for the 
potential identification of  new metabolites and pathways linked to pathophysiological processes and 
disease susceptibility (1–7). For example, in previous studies we used an untargeted mass spectrom-
etry (MS) approach to discover an association between plasma levels of  the metabolite trimethylamine 
N-oxide (TMAO) and incident risk for cardiovascular disease (CVD) (1). Subsequent studies revealed 
TMAO is produced via metaorganismal pathways initiated by ingestion of  trimethylamine-contain-
ing (TMA-containing) dietary nutrients, including phosphatidylcholine (1), choline (1), betaine (1), 
carnitine (8), and γ-butyrobetaine (9). Following ingestion, gut microbial fermentation of  the TMA-
containing nutrient results in TMA release, which upon delivery to the liver via the portal circulation 
is converted into TMAO via host enzymes (1). Further, mechanistic animal models have shown that 
Using an untargeted metabolomics approach in initial (N = 99 subjects) and replication cohorts (N = 
1,162), we discovered and structurally identified a plasma metabolite associated with cardiovascular 
disease (CVD) risks, N6,N6,N6-trimethyl-L-lysine (trimethyllysine, TML). Stable-isotope-dilution 
tandem mass spectrometry analyses of an independent validation cohort (N = 2,140) confirmed 
TML levels are independently associated with incident (3-year) major adverse cardiovascular 
event risks (hazards ratio [HR], 2.4; 95% CI, 1.7–3.4) and incident (5-year) mortality risk (HR, 2.9; 
95% CI, 2.0–4.2). Genome-wide association studies identified several suggestive loci for TML 
levels, but none reached genome-wide significance; and d9(trimethyl)-TML isotope tracer studies 
confirmed TML can serve as a nutrient precursor for gut microbiota–dependent generation of 
trimethylamine (TMA) and the atherogenic metabolite trimethylamine N-oxide (TMAO). Although 
TML was shown to be abundant in both plant- and animal-derived foods, mouse and human fecal 
cultures (omnivores and vegans) showed slow conversion of TML to TMA. Furthermore, unlike 
chronic dietary choline, TML supplementation in mice failed to elevate plasma TMAO or heighten 
thrombosis potential in vivo. Thus, TML is identified as a strong predictor of incident CVD risks in 
subjects and to serve as a dietary precursor for gut microbiota–dependent generation of TMAO; 
however, TML does not appear to be a major microbial source for TMAO generation in vivo.
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dietary provision of  TMA-containing nutrients can result in the gut microbiota–dependent generation 
of  TMA and TMAO, and enhanced atherosclerosis and thrombosis (1, 8–11).
During the conduct of  untargeted metabolomics studies, the majority of  spectral features detected in 
biological matrices arise from metabolites of  unknown structural identity (12). Consequently, unambigu-
ous identification of  the unknowns of  interest requires multiple studies and diverse approaches including 
performance of  multiple distinct case/control studies using different MS and chromatographic techniques 
(to narrow the focus of  efforts to only those unknown analytes that appear to be reproducibly associated 
with the phenotype of  interest), as well as synthesis of  both structural isomers and isotopologues of  candi-
date molecules (for direct comparisons with the unknown analyte). Moreover, once structural elucidation is 
achieved, because untargeted metabolomics studies are intrinsically only semiquantitative, replication stud-
ies using more quantitatively accurate analytical approaches are necessary to validate candidate biomarker 
associations with disease risks. Further, to move beyond association, mechanistic studies are necessary 
to explore potential causal relationships, if  any, between the candidate biomarker and disease. Herein we 
describe our initial structural and subsequent validation and mechanistic studies identifying plasma levels 
of  the unusual free amino acid N6,N6,N6-trimethyl-L-lysine (trimethyllysine, TML) as a strong and inde-
pendent prognostic biomarker of  incident CVD risks in subjects independent of  traditional cardiovascular 
risk factors. We also show TML is a relatively abundant posttranslational modification of  proteins in both 
animal and plants alike, is found in a wide array of  animal and vegetable matter, and can serve as a nutrient 
precursor for gut microbiota–dependent generation of  TMA and TMAO in vivo. Finally, our studies show 
that despite the clear structural and metabolic link between TML and gut microbial TMA/TMAO genera-
tion, the clinical association between circulating TML levels and incident CVD risks in subjects appears to 
be predominantly independent of  TMAO, and that dietary TML does not appear to serve as a major source 
for microbial TMA and TMAO generation compared with choline and carnitine in both mice and humans.
Results
Discovery and structural identification of  TML as a plasma metabolite associated with CVD risks. Our studies that 
ultimately led to the discovery of  a link between TMAO and CVD used an initial case/control design 
(N = 49/50 cases/controls, discovery cohort 1, Table 1) and untargeted MS as a discovery platform (1). 
These studies also disclosed multiple plasma analytes beyond TMAO whose levels were associated with 
CVD based on ion intensities in the semiquantitative untargeted MS experiment. One analyte with an 
unknown structure (mass-to-charge ratio [m/z] of  189.1) appeared to be reproducibly associated with risks 
for both CVD (tertile 3 versus tertile 1, odds ratio [OR], 6.0; 95% CI, 1.7–21.0; P = 0.005) and coronary 
artery disease (CAD) (OR, 6.0; 95% CI, 1.7–21.0; P = 0.005) (Figure 1A). To confirm these initial find-
ings, we performed additional untargeted metabolomics studies in a nonoverlapping cohort of  sequential 
consenting subjects (N = 1,162) undergoing elective diagnostic cardiac evaluation using an alternative 
(high-resolution) MS-based approach, as described in Methods. Baseline characteristics of  this cohort 
(discovery cohort 2) are shown in Table 2. Again, an association between a plasma metabolite with high 
mass accuracy m/z 189.1598 and incident CVD risks was observed. As compared with subjects in the low-
est quartile of  analyte (m/z 189.1598) levels, patients in the highest quartile (Q4) demonstrated a signifi-
cant increased risk of  both incident (3 years) major adverse cardiac events (MACE: myocardial infarction, 
stroke, or death) (hazards ratio [HR], 2.5; 95% CI, 1.4–4.5; P = 0.001), and incident (5-year) mortality 
risk (HR, 2.7; 95% CI, 1.6–4.6; P < 0.001). Following adjustments for traditional CVD risk factors and 
C-reactive protein levels, elevated plasma levels of  the analyte (m/z 189.1598) remained a significant pre-
dictor of  risks of  incident (3-year) MACE (adjusted HR, 2.4; 95% CI, 1.4–4.2; P = 0.003) and mortality 
(5-year; adjusted HR, 2.2; 95% CI, 1.3–3.9; P = 0.005) (Figure 1B).
The collision-induced-dissociation mass spectrum of  the plasma metabolite with m/z 189.1598 revealed 
a molecular cation (M+) with a predicted elemental composition of  C9H21N2O2 (Figure 1C). This informa-
tion, coupled with the observed high-resolution fragmentation pattern (daughter ion m/z and intensities), 
strongly suggested the identity of  the metabolite as TML (Figure 1D and Table 3). Thus, in subsequent 
studies we compared analyte m/z 189.1598 with an authentic synthetic TML standard, and observed identi-
cal MSn and retention time characteristics using multiple different column matrices and chromatography 
conditions, as described under Methods. These data unambiguously confirmed the identity of  analyte m/z 
189.1598 as TML. We therefore synthesized d9(trimethyl)TML for use as an internal standard (Supple-
mental Methods; Supplemental Figure 1 and Supplemental Table 1; supplemental material available online 
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with this article; https://doi.org/10.1172/jci.insight.99096DS1), 
and developed a stable-isotope-dilution liquid chromatogra-
phy with on-line tandem MS (LC-MS/MS) based method for 
quantitative analyses of  TML that was used in all subsequent 
investigations. The method employs 3 unique and characteristic 
parent→daughter ion transitions for monitoring TML and its 
heavy isotope–labeled internal standard, and thus both quantita-
tively measured and further confirmed the identity of  the analyte 
as TML (Figure 1E and Supplemental Figure 2). It should also be 
noted that MS/MS spectra later deposited in MassBank of  North 
America from GNPS (13) and SPLASH (i.e., splash10-001i-
5900000000-3e873bca7eaaf8953194) (14), identified as TML, also 
matched the unknown.
Clinical validation studies confirm that systemic TML levels predict 
incident MACE risks independent of  CVD risk factors. We next exam-
ined whether the association between plasma levels of TML and 
CVD risk could be confirmed using the quantitative stable-isotope-
dilution LC-MS/MS assay in an independent group of subjects (val-
idation cohort). Samples from sequential stable consented patients 
(N = 2,140) undergoing elective diagnostic coronary angiography 
and for whom adjudicated long-term adverse outcomes data were 
available were examined. Baseline demographic, clinical, and lab-
oratory characteristics of the subjects in the validation cohort are 
shown in Table 4. In general, the subjects were middle-aged (62.9 
± 11.1 years), 65% male, had relatively preserved renal function, 
and in majority had either a high burden of CVD risk factors or CAD. Initial examination of the distribution 
of TML levels within the cohort (range 0.17–3.51 μM) showed a significantly higher TML level (P < 0.001) 
among those who experienced a MACE over the ensuing 3-year period following enrollment (Supplemental 
Figure 3). Similarly, higher TML levels were also observed among those who died over a 5-year follow-up 
period (P < 0.001) (Supplemental Figure 3). Kaplan-Meier survival analyses revealed a dose-dependent rela-
tionship between higher TML levels and incident risk for MACE (3 years) and mortality (5 years) (log-rank P 
< 0.001 for each) (Figure 2, A and B). Moreover, compared with subjects in the lowest quartile (Q1) of TML 
levels, subjects in the highest quartile (Q4) demonstrated a significant increased risk of incident MACE (HR, 
2.9; 95% CI, 2.0–4.0; P < 0.001), or death (HR, 3.8; 95% CI, 2.7–5.5; P < 0.001) (Figure 2C). Elevated TML 
(Q4) levels remained an independent predictor of incident MACE (3 years) and mortality (5 years) risks even 
after adjustments for traditional cardiac risk factors and C-reactive protein levels (adjusted model 1, Figure 2C).
Examination of  potential processes impacting TML and CVD risks. Because the structure of  TML contains a 
TMA moiety, we next sought to investigate whether there was a relationship between TML and TMAO lev-
els, as well as whether the prognostic association between TML and CVD risks was dependent on TMAO. 
TMAO was therefore quantified in the same subjects using established stable-isotope-dilution LC-MS/MS 
methods in the entire cohort (15). Of  note, Spearman’s correlation analyses revealed a highly significant 
association between plasma TML and TMAO levels (r = 0.44, P < 0.001; N = 2,140) (Figure 3A). More-
over, as previously observed in multiple cohorts (16–18), TMAO levels within the present cohort were 
associated with all monitored incident adverse CVD events including MACE (3 years) (HR, 2.5; 95% CI, 
1.8–3.5; P < 0.001) and mortality (5 years) risks (HR, 4.0; 95% CI, 2.7–5.8; P < 0.001). When TMAO levels 
were included in the Cox regression models, elevated levels of  both TMAO and TML remained significant 
predictors of  incident (3-year) MACE and incident (5-year) mortality risks after multivariate adjustments 
including CAD status, traditional CVD risk factors, indices of  renal function, and medications (Figure 3, 
B and C). The strength of  the prognostic value of  TML observed in the presence of  TMAO is different 
from that observed with other TMA-containing compounds like choline, carnitine, or betaine, since in 
past studies, the prognostic value of  these TMA and TMAO precursors (choline, carnitine, or betaine) are 
completely abolished following inclusion of  TMAO into statistical models (8, 19). The data observed (Fig-
ure 2C and Figure 3, B and C) thus suggest that some of  the prognostic signal associated with TML and 
incident CVD event risks appears to be independent of  TMAO levels.
Table 1. Baseline characteristics of the patients in discovery cohort 1
Characteristics All (N = 99)
Age (years) 66.3 ± 8.2
Sex, male (%) 52.5
Diabetes mellitus (%) 42.4
History of hypertension (%) 75.3
History of hyperlipidemia (%) 73.7
History of CAD (%) 68.7
Former/Current smokers (%) 62.6
HDL cholesterol (mg/dl) 33.3 (27.7–40)
LDL cholesterol (mg/dl) 99 (82–120)
C-reactive protein (mg/l) 3.8 (1.5–10.7)
eGFR (ml/min/1.73 m2) 83.3 (65.5–92.5)
TMAO (μM) 3.3 (2.4–5.5)
Baseline medications (%)
     Aspirin (%) 76.8
     ACE inhibitors (%) 46.5
     β-Blocker (%) 61.6
     Statin (%) 48.5
Continuous data are presented as mean ± SD or median (interquartile range); 
categorical variables are presented as percentage. CAD, coronary artery 
disease; eGFR, estimated glomerular filtration rate; TMAO, trimethylamine 
N-oxide; ACE, acetylcholine esterase.
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To further examine and illustrate both the independence of  TML and TMAO and their potential addi-
tive prognostic value, we stratified the entire cohort into low, intermediate, and high groups of  both TML 
(cutoffs 0.5, 0.8 μM) and TMAO (cutoffs 2.5, 6.0 μM) levels (Figure 3D and Supplemental Table 2). Nota-
bly, compared with subjects with low levels of  both TML and TMAO (reference group), who experienced 
an absolute annual MACE rate of  2.8%/year, subjects with both high TML and TMAO levels experienced 
a remarkable 10%/year annual event rate, which represents a 4.0-fold increased risk of  incident MACE 
(HR, 4.0; 95% CI, 2.6–6.2; P < 0.001) (Figure 3D and Supplemental Table 2). Moreover, the independence 
of  TML and TMAO clinical prognostic value is further illustrated by noting that even among subjects with 
low TMAO levels, increasing levels of  TML are associated with significant increase in MACE risk (2.7-fold 
risk when TML is high; P = 0.04); and similarly, among subjects with a low TML level, increasing TMAO 
levels dose dependently is associated with increased MACE risk (e.g., 1.9-fold risk when TMAO is concur-
rently high; P = 0.03) (Figure 3D and Supplemental Table 2). Thus, unlike other TMAO nutrient precur-
sors like choline, carnitine, or betaine (8, 19), TML provides independent and additive prognostic value in 
combination with TMAO for prediction of  incident MACE risks.
Given the above results, we next proceeded to explore the potential origins of  the association between 
TML and incident CVD risks. TML can be generated in both free and protein-bound form via lysine meth-
ylation. Methylation of  free lysine to form TML is an initial step in the biosynthetic pathway for carnitine 
(i.e., lysine→TML→γ-butyrobetaine→carnitine) (20, 21). Within the same subjects examined for TML lev-
els (N = 2,140) we therefore also performed stable-isotope-dilution LC-MS/MS analyses of  each of  the 
metabolites in the carnitine biosynthetic pathway using established methods (1, 8, 9, 15). Of  note, each 
Figure 1. Untargeted metabolomics studies discover 
candidate compound with m/z of 189.1598 is associ-
ated with CVD and is trimethyllysine. (A) Forest plot 
indicating plasma metabolite of unknown structure 
with m/z of 189.1 is associated with risk for cardio-
vascular disease (CVD) according to relative peak area 
intensity ranked by tertiles among subjects (N = 99) 
in discovery cohort 1. (B) Forest plot indicating plasma 
metabolite of unknown structure with high-resolu-
tion m/z of 189.1598 is associated with the risk for 
incident CVD and mortality risks according to relative 
peak intensity from untargeted mass spectrometry 
analyses of subjects (N = 1,162; discovery cohort 2). 
MACE, major adverse cardiac events, including myo-
cardial infarction, stroke, or death. The analyses were 
performed using R 3.4.1. (C) Collision-induced dis-
sociation (CID) spectrum in positive-ion mode of the 
metabolite m/z of 189.1598 in plasma. (D) CID spectra 
in positive mode of synthetic trimethyllysine (TML) 
standard. (E) Demonstration of cochromatography of 
multiple unique parent→daughter ion transitions for 
plasma analyte m/z 189.1598 and synthetic d9-TML.
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metabolite demonstrated a significant correlation with plasma 
TML levels (Spearman’s correlation coefficients of  TML with 
lysine [r = 0.16, P < 0.001]; γ-butyrobetaine [r = 0.43, P < 0.001]; 
and carnitine [r = 0.28, P < 0.001]). Protein-bound TML is also 
generated as a common posttranslational modification of  protein 
lysine residues, particularly histones during chromatin remodel-
ing and transcriptional regulation (22, 23); however, the presence 
and distribution of  protein-bound TML in secreted proteins with-
in plasma has been largely unexplored. We therefore examined 
the relationship between plasma free TML levels versus protein-
bound TML in plasma proteins recovered (see Methods) from 
a random set of  subjects (N = 25). Remarkably, the content of  
total protein-bound TML in plasma proteins was highly corre-
lated with free TML among all subjects (Spearman’s correlation 
r = 0.82, P < 0.001), as well as among both healthy controls (r = 
0.69, P < 0.01; N = 16), and subjects with CVD (r = 0.95, P < 
0.001; N = 9) (Figure 3E).
The factors that contribute to variations in plasma TML lev-
els among subjects are largely unexplored. We therefore sought 
to test whether we could identify genetic determinants of  plasma 
TML levels using an unbiased genome-wide association study 
(GWAS) approach. Of  the 2,140 subjects with TML levels, 1,297 
also had data for 9,012,028 imputed autosomal single-nucleotide 
polymorphisms (SNPs). As shown by the Manhattan plot (Figure 4), no locus exceeded the genome-wide 
significant P value of  5.0 × 10–8, but several SNPs (mostly with minor allele frequencies [MAFs] ≤ 5%) on 
chromosomes 1, 3, 5, 6, and 8 exhibited suggestive evidence of  association (P < 5.0 × 10–7) (Table 5). We 
also specifically looked at 400-kb regions surrounding the genes encoding 27 known lysine methyltransfer-
ases (24), but none of  these candidate loci yielded evidence of  association with TML levels either. We next 
used the results from the CARDIoGRAM Consortium (25) to determine whether any of  the 6 suggestively 
associated regions/loci for plasma TML levels were associated with risk of  CVD. Data were available for 5 
of  these loci, but none of  these were associated with risk of  CVD in CARDIoGRAM (Table 6).
Since both plant and animal cells alike use histone protein methylation to regulate gene expression, we 
wondered whether TML (free plus protein bound) could be a potentially unrecognized yet abundant nutri-
ent precursor for TMAO generation from plant- and animal-derived foods. To examine the relative levels 
and distribution of  TML versus other major TMAO nutrient precursors in common foods, we quantified 
total (free + esterified or protein-bound) levels of  TML, choline, and carnitine in a variety of  animal- and 
plant-derived foods (Table 7). Surprisingly, TML was found in virtually all food sources, though in general, 
at a greater level in animal- versus plant-derived products. Thus, when compared with total choline or total 
carnitine content in foods, TML was present at surprisingly abundant levels (Table 7).
Dietary TML can generate TMA and TMAO via gut microbiota. Given the presence of  TML in so many 
food sources, we next examined whether dietary TML could serve as a substrate for microbiota-dependent 
generation of  TMA and TMAO. We initially performed oral (gastric gavage) challenges in mice using 
Table 2. Baseline characteristics of the patients in discovery cohort 2
Characteristics  Angiographic cohort (N = 1,162)
Age (years) 64.0 ± 10.9
Sex, male (%) 63.7
Diabetes mellitus (%) 22.1
History of hypertension (%) 72.1
History of hyperlipidemia (%) 85.8
Former/current smoking (%) 65.4
History of CAD (%) 75.6
HDL cholesterol (mg/dl) 34.3 (28.5–41.2)
LDL cholesterol (mg/dl) 96.0 (80.0–116.0)
C-reactive protein (mg/l) 2.3 (1.0–5.4)
eGFR (ml/min/1.73 m2) 85.0 (71.4–94.8)
Baseline medications (%)
     Aspirin (%) 76.8
     ACE inhibitors (%) 49.9
     β-Blocker (%) 65.3
     Statin (%) 61.4
Continuous data are presented as mean ± SD or median (interquartile range), 
categorical variables are presented as percentage. CAD, coronary artery disease; 
eGFR, estimated glomerular filtration rate; ACE, acetylcholine esterase.
 
Table 3. Comparison of experimental high-resolution mass data from analyte m/z 189.1598 in plasma versus predicted m/z for parent 
and daughter ions of TML
Analyte Elemental composition Theoretical m/z Measured m/z Delta (ppm)
TML C9H21N2O2 189.1603 189.1598 2.64
Daughter 1 C3H10N  60.0813  60.0810 4.99
Daughter 2 C5H10N  84.0813  84.0808 5.95
Daughter 3 C6H12NO2 130.0868 130.0863 3.84
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either synthetic d9(trimethyl)-TML (see Supplemental Meth-
ods for synthesis and characterization) or d9(trimethyl)-cho-
line, and monitored serial plasma samples over time for quan-
tification of  isotope-labeled parent compound and d9-TMA 
and d9-TMAO levels. Following oral d9-TML gavage of  
conventionally reared C57BL/6J mice, plasma levels of  both 
d9-TMA and d9-TMAO rose only minimally following a lag 
phase, despite a rapid (within 1 hour) increase in d9-TML 
level following ingestion (Figure 5, A–C). By comparison, 
identically challenged C57BL/6J mice with the same (molar) 
amount of  oral d9-choline demonstrated markedly (30- to 
50-fold) higher peak levels of  d9-TMA and d9-TMAO, and 
substantially lower plasma levels of  isotope-labeled precursor 
(d9-choline) (Figure 5, D–F). These results directly demon-
strate that oral TML can serve as a precursor for TMA and 
TMAO generation. Of  note, however, compared with com-
parable oral challenge of  choline, TML was a much poorer 
precursor for TMA and TMAO formation in vivo.
To determine whether gut microbes are involved in dietary 
TML-dependent generation of  TMAO, parallel studies were 
performed in mice before versus after a 3-week exposure to 
a cocktail of  oral poorly absorbed broad-spectrum antibiot-
ics previously shown to markedly suppress gut microbiota 
(1, 26). Notably, despite initial generation of  TMAO before 
antibiotics (Figure 5G), no detectable plasma d9-TMAO was 
observed following d9-TML oral gavage in mice treated with 
the oral antibiotics (Figure 5G). Further, the pretreatment with oral antibiotics had no impact on plasma 
d9-TML levels following oral gavage (P = 0.87). Collectively, these results are consistent with gut microbial 
involvement in TMA and TMAO generation from dietary TML, albeit at a level substantially lower than 
observed with dietary choline.
Characterization of  mouse and human gut bacteria–dependent generation of  TMA from TML. Initial studies 
examining cecal contents recovered from conventionally reared mice revealed d9-TMA generation from 
d9-TML under anaerobic (but not aerobic) culture conditions, as described under Methods. We therefore 
examined the anatomical distribution of  gut microbiota capable of  producing d9-TMA from d9-TML in 
intestinal contents recovered from segments harvested from conventionally raised mice and cultured in an 
anaerobic chamber. To permit direct comparisons, we also performed side-by-side anaerobic cultures using 
comparable amounts of  2 alternative TMA-producing nutrient precursors, d9-carnitine and d9-choline 
(Figure 6A). Interestingly, microbes recovered from both cecal and colonic segments generated d9-TMA 
from d9-TML under anaerobic culture, and significantly lower but detectable levels of  d9-TMA were also 
formed from d9-TML incubated with small-bowel microbes. By comparison, only cecal and colonic micro-
biota converted d9-carnitine or d9-choline into d9-TMA. Notably, the synthetic capacity of  cecal microbi-
ota to generate d9-TMA from d9-carnitine was 10-fold higher than that observed with d9-TML, and 1,000-
fold higher from a comparable exposure to d9-choline. These data thus reveal a nutrient TMA-generating 
potential from murine gut commensals of  TML < carnitine << choline (Figure 6A).
We next sought to examine known culturable human commensals to identify specific microbial spe-
cies capable of  using TML as substrate to generate TMA. We began with studies employing a panel of  68 
culturable human commensals, representing a large fraction of  the diversity observed in the human gut, 
including the 7 most abundant bacterial phyla and 28 different genera. This library was previously used to 
identify species capable of  converting choline into TMA (i.e., through choline TMA lyase activity) (27). 
Eighteen individual members of  the human commensal library were initially screened under anaerobic 
conditions as previously described for detecting choline TMA lyase activity using d9-choline as substrate, 
but this time adding d9-TML to media, as described under Methods. Despite the ability of  several strains to 
convert d9-choline→d9-TMA under these conditions, none of  these species significantly promoted conver-
sion of  d9-TML→d9-TMA (data not shown). We next examined whether a pool containing all 68 species 
Table 4. Baseline characteristics of the patients in the validation cohort
Characteristics Angiographic cohort (N = 2,140)
Age (years) 62.9 ± 11.1
Sex, male (%) 65.2
Diabetes mellitus (%) 40.8
History of hypertension (%) 72.7
History of hyperlipidemia (%) 85.2
Former/current smoking (%) 65.4
History of CAD (%) 74.5
HDL cholesterol (mg/dl) 33.9 (28.2–40.6)
LDL cholesterol (mg/dl) 96.0 (79.0–116.0)
C-reactive protein (mg/l) 2.6 (1.1–6.3)
eGFR (ml/min/1.73 m2) 86.7 (72.3–96.4)
TMAO (μM) 3.7 (2.5–6.2)
TML (μM) 0.53 (0.43–0.70)
Baseline medications (%)
     Aspirin (%) 75.1
     ACE inhibitors (%) 50.1
     β-Blocker (%) 63.2
     Statin (%) 60.7
Continuous data are presented as mean ± SD or median (interquartile range), 
categorical variables are presented as percentage. CAD, coronary artery disease; 
eGFR, estimated glomerular filtration rate; TMAO, trimethylamine N-oxide; TML, 
trimethyllysine; ACE, acetylcholine esterase.
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(grown individually and mixed in similar proportions prior to the assay) could promote the conversion of  
d9-TML→d9-TMA, speculating that perhaps the observed activity in cultured cecal/colonic contents, and 
in vivo (mouse isotope tracer studies), might occur via sequential metabolic transformations promoted by 
more than one microbe. Unfortunately, however, virtually no detectable d9-TML→d9-TMA transforma-
tion was observed with pooled microbes in prolonged (4 days) incubation (assay limit of  detection, ~1 
nM). These results suggest that conversion of  TML to TMA is a relatively rare trait, possibly restricted to a 
specific taxonomic group not represented in our screen, or possibly inactive under the screening conditions.
Given that d9-TML is clearly converted into d9-TMA in a gut microbiota–dependent fashion in 
vivo in mice (Figure 5), and in anaerobic cultures of  either mouse cecal or colonic contents (Figure 6A), 
we next decided to examine human polymicrobial fecal anaerobic cultures for their capacity to convert 
d9-TML→d9-TMA. Human feces from both healthy volunteer omnivores (N = 10 or more) and vegans 
(N = 8) were examined for d9-TMA generation from equivalent amounts of  d9-TML versus the alterna-
tive TMA precursor nutrients, d9-carnitine and d9-choline, under anaerobic culture conditions. Notably, 
feces from omnivores and vegans alike promoted the transformation of  d9-TML→d9-TMA, with omni-
vores having significantly greater activity than vegans (P < 0.04; Figure 6B). However, the overall level 
of  TMA generation from TML was relatively low, with d9-carnitine→d9-TMA transformation showing 
a comparable degree of  d9-TMA formed in vegans. Remarkably, over a 100-fold greater production 
of  d9-TMA was produced from d9-carnitine incubated with polymicrobial fecal cultures from omni-
vores (Figure 6B). Even more notable was the observation that d9-choline→d9-TMA conversion within 
anaerobic cultures from human feces recovered from vegan and omnivore alike were both approximately 
3 orders of  magnitude greater than the levels of  d9-TMA produced from d9-TML (Figure 6B). These 
studies thus revealed a nutrient TMA-generating potential from human fecal commensals of  TML < 
carnitine << choline, similar to results observed with mouse cecal and colonic microbiota.
In a final series of  studies aimed at examining gut microbial participants in TMA/TMAO generation, 
we examined whether recombinant forms of  known microbial enzymes capable of  generating TMA with 
Figure 2. Stable-isotope-dilution LC-MS/MS analyses 
verify systemic levels of TML are associated with incident 
cardiovascular disease risks independent of TMAO. Kaplan-
Meier estimates and 3-year risks (HR [95% CI]) for (A) major 
adverse cardiac events (MACE, including myocardial infarc-
tion, stroke or death); and (B) all-cause mortality (5 years) 
ranked by trimethyllysine (TML) quartiles in the validation 
cohort (N = 2,140). (C) Forest plots indicate the HR (95% CI) 
for incident (3-year) risks for MACE and all-cause mortality 
(5-year) according to TML quartiles. HR (unadjusted, open 
circles) and multivariable Cox model 1 adjusted (filled black 
circles; adjusted for age, sex, high-density lipoprotein [HDL], 
low-density lipoprotein [LDL], smoking, diabetes mellitus, 
hypertension, C-reactive protein level), or model 2 adjusted 
(filled red squares, adjusted for model 1 plus trimethylamine 
N-oxide [TMAO]). The 5%–95% confidence interval is indicated 
by line length. The analyses were performed using R 3.4.1. HR, 
hazard ratio.
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alternative substrates could instead use TML as substrate to produce TMA. We thus examined transformed 
E. coli expressing the genes cutC/D, yeaX/W, or cntA/B, microbial TMA-generating enzyme systems previ-
ously reported for their capacity to use choline-related, or carnitine-related substrates (28–30). With E. coli 
transformed individually with each recombinant enzyme system, and despite observing enzymatic activity 
(TMA generation) with previously reported substrates for generating TMA from the given microbial TMA 
lyases, none of  the known recombinant microbial TMA generating enzyme systems examined supported 
d9-TML conversion into d9-TMA (Figure 6C).
Figure 3. Relationship between plasma TML and both CVD risks and TMAO. (A) Correlation between plasma levels of trimethyllysine (TML) and 
trimethylamine N-oxide (TMAO) in the validation cohort (N = 2,140). (B) Kaplan–Meier plot illustrating the relationship between plasma TML and risk 
of incident (3-year) major adverse cardiac events (MACE); and (C) incident (5-year) mortality risk according to TML and TMAO levels where each marker 
is categorized above versus below the median level in the validation cohort (N = 2,140). Also shown are hazard ratio (HR [95% CI]) for the indicated 
TML and TMAO grouping using either an unadjusted model, or following adjustments for traditional cardiovascular disease (CVD) risk factors (age, sex, 
HDL, LDL, smoking, diabetes mellitus, hypertension), high-sensitivity C-reactive protein level, estimated glomerular filtration rate (eGFR ), history of 
CAD and medications. Median plasma concentration of TML (0.53 μM) and TMAO (3.69 μM) within the cohort was used to stratify subjects as high 
(≥median) or low (<median) values. (D) Plot of HR for incident 3-year MACE risk stratified by indicated low, intermediate, and high levels of TMAO 
(cutoff values of 2.5 and 6 μM) and TML (cutoff values of 0.5 and 0.8 μM). *P < 0.05, **P < 0.01, ***P < 0.001 relative to low/low TMAO/TML group. 
(E) Comparison of plasma levels of TML in free form versus protein-bound TML levels in random samples from both healthy subjects and subjects with 
CVD, as indicated. The analyses were performed using R 3.4.1.
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Impact of  chronic dietary TML versus choline supplementation on systemic TMAO levels and in vivo thrombo-
sis potential. In previous studies we have shown that chronic provision of  a dietary nutrient can lead to 
enhanced gut microbial community capacity to form TMA and raise systemic TMAO levels (8). Since 
TML→TMA conversion in human fecal polymicrobial cultures derived from omnivores was significant-
ly greater than that observed from vegans (Figure 6B), we hypothesized that chronic dietary exposure 
may enhance gut microbiota–dependent conversion of  TML→TMA. We therefore sought to investigate 
the impact of  chronic dietary TML supplementation on plasma TMAO levels and in vivo thrombosis 
potential in mice. Since a large amount of  TML is not readily commercially available, before proceed-
ing, we synthesized and chemically characterized sufficient quantities of  TML for the proposed in vivo 
studies (Supplemental Figure 4 and Supplemental Table 3). In addition, for direct comparison, parallel 
mouse studies were performed using chronic supplementary (1%) dietary choline. Provision of  supple-
mental dietary TML (1%) to mice for up to 11 days resulted in a highly significant, nearly 100-fold 
increase in plasma TML levels (P < 0.0001) but no significant increase in systemic TMAO levels (Figure 
7, A and B). By comparison, provision of  the comparable amount of  supplemental dietary choline (1%) 
significantly (~20-fold) raised plasma TMAO levels (P < 0.0001, Figure 7C). We further tested if  elevat-
ed plasma TML in mice fostered enhanced thrombosis potential in vivo using a FeCl3-induced carotid 
Figure 4. Results of a GWAS for plasma TML levels in the GeneBank cohort. The Manhattan plot for plasma TML levels (N = 1,297 subjects) shows 6 sug-
gestively associated loci on chromosomes 1q44, 3p24.1, 5p15.33, 6p24.1, 6q23.3, and 8p21.2. The genome-wide thresholds for significant (P = 5.0 × 10–8) and 
suggestive (P = 5.0 × 10–7) association are indicated by the horizontal red and blue lines, respectively. P values were obtained using linear regression with 
natural-log-transformed values and adjustment for age and sex.
Table 5. Lead SNPs at loci identified for plasma TML levels in the GeneBank cohort
SNP Chromosome PositionA AllelesB EAFC βD ± SE P valueD
rs34568450 1q44 244,489,956 G/A 0.10 0.114 ± 0.023 4.8 × 10–7
rs75233056 3p24.1 28,192,633 A/T 0.06 0.158 ± 0.030 1.1 × 10–7
rs11133993 5p15.33 3,568,737 A/G 0.28 0.077 ± 0.015 4.7 × 10–7
rs78078192 6p24.1 13,320,526 G/A 0.02 0.252 ± 0.048 2.2 × 10–7
rs150604736 6q23.3 137,385,027 A/G 0.01 0.287 ± 0.056 3.0 × 10–7
rs562044044 8p21.2 26,462,015 G/T 0.01 0.301 ± 0.057 1.3 × 10–7
ABase pair positions are given according to NCBI build 37 (hg19) of the reference human genome sequence. BSNP alleles are shown as effect allele/
other allele. CEAF indicates effect allele frequency. Dβ ± SE refers to the effect allele, and P values were obtained by linear regression using natural-log-
transformed values, assuming an additive genetic model, and with adjustment for age and sex.
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artery injury model, as described in Methods. The impact of  a comparable amount of  choline supple-
mentation on in vivo thrombosis potential was similarly examined for comparison. As shown in Figure 
7D, chronic dietary TML failed to significantly change thrombus formation rate, or time to cessation of  
blood flow, in the carotid artery injury in vivo thrombosis model (Figure 7D). In contrast, however, as 
previously observed with choline supplementation (11), significant TMAO elevations were accompanied 
by enhanced in vivo thrombosis potential, as monitored via reduction in time to cessation of  blood flow 
of  the carotid artery following FeCl3-induced injury (Figure 7D).
Discussion
Herein we utilized untargeted metabolomics to discover that systemic levels of  the unusual free amino acid, 
TML, are strikingly associated with incidence of  CVD risks independent of  multiple cardiometabolic risk 
factors, prevalent CVD, and medication use. Our studies also reveal that TML, a TMA-containing com-
pound, is surprisingly abundant in both plant- and animal-derived foods alike, and that gut microbiota have 
evolved enzymatic machinery to metabolize TML. Nonetheless, our studies show that in gut commensals 
Table 6. Association of suggestive loci for plasma TML levels with risk of CVD
SNP EA (Frequency) OR (95% CI) P value
rs34568450 A (0.85) 0.98 (0.95–1.01) 0.13
rs75233056 T (0.93) 0.98 (0.94–1.03) 0.42
rs11133993 G (0.73) 1.01 (0.99–1.03) 0.34
rs78078192 A (0.97) 1.00 (0.94–1.05) 0.88
rs150604736 G (0.98) 0.96 (0.88–1.05) 0.38
Odds ratio (OR) and 95% confidence interval (CI) refer to the effect allele (EA) and were obtained from the results of the CARDIoGRAM Consortium. TML, 
trimethyllysine; CVD, cardiovascular disease.
 
Table 7. Total trimethyllysine, carnitine, and choline content in some common foods
Foods Trimethyllysine (mg/100 g) Carnitine (mg/100 g) Choline (mg/100 g)
Vegetable
     White onion 0.40 0.03 6.04
     Cucumber 0.74 0.02 6.42
     Tomato 0.81 0.14 7.99
     Carrot 0.65 0.07 11.96
Dairy and Egg
     Cheese 4.31 0.63 16.44
     Whole milk 0.72 0.85 8.0
     Butter 0.34 0.35 12.49
     Whole Egg 13.68 0.89 253.0
Sea food
     Tuna 5.56 1.28 19.29
     Salmon 4.84 0.60 65.81
     Shrimp 12.25 1.25 27.35
Meat
     Chicken 0.97 1.20 22.34
     Turkey 5.82 4.66 49.60
     Pork 4.31 2.27 39.95
     Veal 6.05 18.06 38.61
     Lamb 2.36 21.98 40.29
     Deer 4.10 22.16 33.63
     Goat 8.63 20.59 48.08
     Beef 6.12 38.42 60.97
     Beef liver 3.66 0.52 271.6
The data shown are for total (free plus esterified or protein-bound) trimethyllysine, choline, or carnitine content in some common foods.
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from both mice and humans, the utilization of  TML as nutrient precursor for TMA and TMAO formation 
is a relatively modest microbial activity compared with microbiota-dependent conversion of  choline, and to 
lesser extent, carnitine (especially in omnivores). Further, gut microbial transformation of  TML into TMA 
occurs via enzyme(s) distinct from known microbial choline or carnitine TMA lyases, such as cutC/D, 
cntA/B, or yeaW/X.
Despite the observed association between TML and incident CVD risks, the underlying mechanism(s) 
accounting for the strong association remain unclear. One obvious mechanism that was extensively 
explored was the potential capacity of  TML to form TMA and the atherogenic and prothrombotic metabo-
lite TMAO. However, multiple lines of  evidence suggest that mechanisms alternative to TMAO account 
for the observed association between TML and incident CVD risks. First, in clinical studies, adjustment for 
TMAO in Cox models failed to significantly attenuate the clinical prognostic value of  TML and incident 
CVD risks. This behavior contrasts with that observed with other TMA nutrient precursors like choline, 
betaine, or carnitine, which lose their clinical prognostic value for incident CVD risks when TMAO levels 
are included in multilogistic regression models (8, 19). Further, despite observing gut microbiota–depen-
dent generation of  TMA and TMAO from TML, plasma levels of  TMAO were not affected by dietary 
TML. Thus, in contrast to choline supplementation, which raises TMAO levels and increases in vivo 
thrombosis potential (11), chronic TML supplementation both failed to raise TMAO levels and did not 
enhance in vivo thrombosis potential as monitored using a carotid artery injury model. Lastly, to try and 
identify factors that may be linked to systemic TML levels and CVD risk, we performed a GWAS study 
in approximately 1,300 subjects. While several suggestive loci were identified, none reached genome-wide 
significance or yielded evidence of  association with risk of  CVD.
An intriguing finding in the present study is the remarkably tight correlation observed between protein-
bound TML and free TML levels. These results raise the prospects that free TML levels may reflect the 
level of  protein-bound TML in the vascular compartment. They thus suggest that further investigation into 
defining which proteins in plasma are modified through lysine methylation is of  interest. Even more so, 
it will be of  interest to explore whether posttranslational modification of  plasma or vascular wall proteins 
alters their function. In this respect, it is intriguing to note that lysine methylation plays a critical role in 
the histone code and the overall regulation of  chromatin remodeling and transcriptional gene control. 
While lysine methylation was originally proposed to be an irreversible posttranslational modification on 
proteins, it has recently been recognized that protein lysine residue methylation (at least for histones) can 
be reversible, with multiple demethylases discovered (31–33). With discovery of  protein-bound TML pres-
ent in plasma and its remarkably high correlation with free TML, the role of  protein lysine methylation in 
both the secreted proteome and proteins within the vascular wall and other organs is of  interest. Moreover, 
whether the protein-bound TML detected in the vascular compartment is a reversible posttranslational 
modification, like in histones, is similarly of  interest.
It is remarkable that the present studies identify yet another TMA-containing metabolite, TML, with 
links to both TMA and TMAO generation and significant clinical prognostic value for incident adverse car-
diovascular event risks. Of  note, in contrast to choline or carnitine, chronic dietary TML fails to significant-
ly change plasma TMAO levels, and in this respect, TML behaves somewhat like betaine, which similarly 
was identified through untargeted metabolomics as having plasma levels associated with incident MACE 
risks (1), and which can be a TMA nutrient precursor, albeit also at a rate about 100-fold less than choline 
(19). The present studies reaffirm the promise of  untargeted metabolomics as a platform for discovery of  
candidate metabolites and pathways with links to disease processes. They substantially expand our under-
standing of  TML and its association with CVD risks, and suggest further exploration of  the pathobiology 
of  protein lysine methylation, and the biological processes that modulate free TML levels are of  interest.
Methods
Clinical study population. Plasma samples, feces, and associated clinical data were collected as part of  2 studies 
at a tertiary care center. Metabolomics studies were performed on GeneBank samples, a large (N > 10,000) 
well-characterized and longitudinal tissue repository with associated clinical database. It comprised sequen-
tial participants enrolled in the study GeneBank, which consists of  sequential stable subjects without evidence 
of  acute coronary syndrome (cardiac troponin I < 0.03 ng/ml) who underwent elective diagnostic coronary 
angiography (cardiac catheterization or coronary computed tomography) for evaluation of  CAD (1, 16, 34). 
All subjects had extensive clinical and longitudinal outcome data monitored, including adjudicated outcomes 
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over the ensuing 3 to 5 years for all participants after enrollment. MACE was defined as death, nonfatal myo-
cardial infarction, or nonfatal cerebrovascular accident (stroke) following enrollment. Initial discovery metab-
olomics analyses began with an unbiased search for plasma analytes linked to CVD risk using a case/control 
design (49 cases and 50 controls, discovery cohort 1). Cases were randomly selected from GeneBank subjects 
who experienced a myocardial infarction, stroke, or death over the ensuing 3-year period following enroll-
ment (1). For controls, an age- and gender-matched group was randomly selected from GeneBank subjects 
that did not experience a CVD event. An independent nonoverlapping cohort (N = 1,162, discovery cohort 
2) for untargeted metabolomics was also derived from sequential consenting subjects enrolled in GeneBank. 
Figure 5. d9-TML and d9-choline oral isotope tracer studies. Synthetic d9-TML or d9-choline was administered by gastric gavage to the indicated numbers 
of C57BL/6J mice and serial plasma levels of the indicated isotope-labeled compounds were quantified by LC-MS/MS, as described under Methods. (A–C) 
Plasma levels of d9-trimethylamine (d9-TMA), d9-trimethylamine N-oxide (d9-TMAO), and d9-trimethyllysine (d9-TML) are shown at the indicated times 
following oral challenge with time of d9-TML gavage designated as T = 0. (D–F) Plasma d9-TMA, d9-TMAO, or d9-choline at the indicated times follow-
ing oral d9-choline challenge. (G) Plasma concentrations of d9-TMAO were also quantified by LC-MS/MS in C57BL/6J female mice at the indicated times 
following challenge with d9-TML via gastric gavage, either before or following 3-week administration of a cocktail of broad-spectrum poorly absorbed 
antibiotics, as described under Methods. All data are presented as mean ± standard error.
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A third large independent nonoverlapping validation cohort (N = 2,140) was also from sequential consenting 
subjects enrolled in GeneBank. Fasting blood glucose, high-sensitivity C-reactive protein, and lipid profiles 
were measured on the Roche Cobas platform (Roche Diagnostics).
In additional studies, healthy volunteers (N = 15 omnivores and N= 8 vegetarians or vegans) were 
consented and subjected to extensive dietary questioning and stool collection as part of  a study examining 
gut microbiota–dependent metabolism of  dietary carnitine and CVD (8). Only feces at baseline were used. 
Male and female volunteers were at least 18 years of  age. Volunteers participating were excluded if  they 
were pregnant, had chronic illness (including a known history of  heart failure, renal failure, pulmonary 
disease, gastrointestinal disorders, or hematologic diseases).
Initial metabolomics analyses. In general, the initial untargeted metabolomics approach used was similar 
to that described previously (1, 8). Plasma proteins were precipitated with 4 volumes of  ice-cold methanol 
and small-molecule analytes within supernatants were analyzed after injection onto a phenyl column (4.6 
× 250 mm, 5 μm Rexchrom Phenyl; Regis) at a flow rate of  0.8 ml/min using a Cohesive HPLC inter-
faced with a PE Sciex API 365 triple-quadrupole mass spectrometer (Applied Biosystems) with Ionics 
HSID1, EP101, XT1 redesigned source and collision cell as upgrades in positive MS1 mode. LC gradient 
(LC1) starting from 10 mM ammonium formate over 0.5 minutes, then to 5 mM ammonium formate, 25% 
methanol and 0.1% formic acid over 3 minutes, held for 8 minutes, followed by 100% methanol and water 
washing for 3 minutes at a flow rate of  0.8 ml/min was used to resolve analytes. Spectra were continuously 
acquired after the initial 4 minutes. Peaks within reconstructed ion chromatograms at 1–atomic mass unit 
increments were integrated and both retention times and m/z of  analytes were used for statistical analyses.
Figure 6. Characterization of microbial TMA formation 
from TML versus alternative TMA-generating nutrients 
in mouse intestines, human fecal cultures, and cloned 
microbial TMA lyases. (A) Intestines from conventionally 
reared C57BL/6J mice (N = 7) were sectioned as indicated, 
incubated with either d9-trimethyllysine (d9-TML), d9-car-
nitine, or d9-choline anaerobically, and then production 
of d9-trimethylamine (d9-TMA) quantified as described 
in Methods. (B) Human feces from vegans (N = 8) and 
omnivores (N = 10–15 as indicated) were incubated with 
either d9-TML, d9-carnitine, or d9-choline anaerobically, 
and then production of d9-TMA quantified as described in 
Methods. Student’s t test (2 tailed) was used to examine 
the difference between groups. All data are presented 
as mean ± standard error. (C) Recombinant microbial 
TMA lyases were cloned and expressed, and then activity 
(production of d9-TMA) with the indicated d9-labeled 
substrates determined as described under Methods.
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To chemically define the structures of  the plasma analyte selected for further investigation (that is, 
candidate compound with m/z 189.1 in positive MS1 mode). TML in plasma was identified by HPLC/
high-resolution mass spectrometer with the same retention time, high-resolution mass, and fragmented 
ions as standard. Plasma supernatant after methanol precipitation of  protein was analyzed by injec-
tion onto a silica column (2.0 × 150 mm, 5 μm Luna silica; catalog 00G-4274-B0, Phenomenex) using 
a 2 LC-20AD Shimadazu pump system, SIL-HTC autosampler interfaced with a TripleTOF 5600 
mass spectrometer (AB SCIEX). Separation was performed employing a gradient starting at 100% A 
(10 mM ammonium acetate aqueous solution) for 2 minutes, then increasing linearly to 20% B (ace-
tonitrile/methanol/acetic acid, 50:50:0.1, v/v/v) over 8 minutes followed by 100% B washing for 5 
minutes and 100% A balancing for 5 minutes. The parameters for the ion monitoring were as follows: 
spray voltage, 5.5 kV; curtain gas, 20; GS1, 20; GS2, 15; DP, 30; CE, 30 volts, CES, 15 volts. Nitrogen 
(99.95% purity) was used as the only gas.
To confirm the identity of  plasma analyte 189.1 as TML, the plasma analyte and synthetic d9-TML 
standard were examined on multiple different column matrices and chromatography conditions:
System 1: column (2.0 × 150 mm, 5 μm Luna silica; catalog 00G-4274-B0, Phenomenex), sepa-
rated on discontinuous gradient composed of  mobile phase A (0.1% propionic acid in water ) versus 
mobile phase B (0.1% acetic acid in methanol) starting at 100% A for 2 minutes, then increasing lin-
early to 15% B over 8 minutes followed by 100% B washing for 5 minutes and balancing for 5 minutes; 
the flow rate was 0.2 ml/min. System 2: column (2.0 × 50 mm, 1.9 μm Titan silica; catalog 581530-
U, Supelco), separated on discontinuous gradient composed of  mobile phase A (10 mM ammonium 
formate and 0.1% formic acid in water ) versus mobile phase B (10 mM ammonium formate and 0.1% 
formic acid in acetonitrile) starting at 100% B linearly decreasing to 100% A over 4 minutes followed 
by washing with 100% A for 0.5 minutes and balancing with 100% B for 0.5 minutes; the flow rate 
was 0.4 ml/min. System 3: column (2.0 × 150 mm, 3 μm Scherzo SM-C18; catalog SM025, Imtakt) 
separated on discontinuous gradient composed of  mobile phase A (0.1% formic acid in water ) versus 
Figure 7. Impact of TML- versus choline-supple-
mented diet on plasma levels of TML and TMAO, 
and in vivo thrombosis potential. Groups of mice 
(N = 15) were placed on chemically defined diets 
supplemented with either 1% trimethyllysine 
(TML) (A and B) or 1% choline (C) for 11 days as 
described under Methods. At the indicated times, 
plasma levels of trimethylamine N-oxide (TMAO) 
(A and C) or TML (B) were quantified by stable-
isotope-dilution LC-MS/MS. (D) In addition, after 
11 days of the indicated diet (N = 10), the impact 
of supplemental dietary TML versus choline on 
both TMAO levels and in vivo thrombosis poten-
tial, as monitored using the FeCl3 carotid artery 
injury model, was determined as described under 
Methods. Plasma levels of metabolites after 11 
days of the indicated diets were as follows: for 1% 
TML group, TMAO =4.5 ± 0.7 μM, TML = 37.0 ± 4.9 
μM. For 1% choline group, TMAO = 90.6 ± 19.5 μM, 
TML = 0.8 ± 0.1 μM. For chemically defined chow 
group, TMAO= 2.6 ± 0.4 μM; TML = 0.9 ± 0.2 μM. 
Student’s t test (2 tailed) was used to examine the 
difference between groups. All data are presented 
as mean ± standard error.
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mobile phase B (0.1% formic acid in methanol) starting at 100% A for 2 minutes, then increasing lin-
early to 15% B over 7 minutes followed by 100% B washing for 3 minutes and balancing for 3 minutes; 
the flow rate was 0.3 ml/min.
Untargeted analysis of  plasma samples using HILIC-MS. Untargeted analysis of  plasma samples was simi-
lar to that described previously (35, 36). In brief, extraction of  plasma metabolites was carried out using 
an acetonitrile/isopropanol/water (3:3:2, v/v/v) mixture. Aliquots were evaporated, resuspended using an 
acetonitrile/water (4:1, v/v) mixture, vortexed, centrifuged, and the upper layer transferred to a glass vial 
with a microinsert. Hydrophilic interaction chromatography (HILIC) analysis was performed on a system 
including an Agilent 1290 Infinity LC system (Agilent Technologies) with a pump (G4220A), a column 
oven (G1316C), an autosampler (G4226A), and a TripleTOF 5600+( SCIEX). Extracts were separated 
on an Acquity UPLC BEH Amide column (150 × 2.1 mm; 1.7 μm, Waters) coupled to a Waters Acquity 
UPLC BEH Amide VanGuard precolumn (5 × 2.1 mm; 1.7 μm). The column was maintained at 45°C at a 
flow rate of  0.4 ml/min. The mobile phases consisted of  (A) water with ammonium formate (10 mM) and 
formic acid (0.125%) and (B) 95:5 (v/v) acetonitrile/water with ammonium formate (10 mM) and formic 
acid (0.125%). The separation was conducted under the following gradient: 0 min 100% B; 0–2 min 100% 
B; 2–7.7 min 70% B; 7.7–9.5 min 40% B; 9.5–10.25 min 30% B; 10.25–12.75 min 100% B; 12.75–17.75 
min 100% B. A sample volume of  1 μl was used for the injection. Sample temperature was maintained at 
4°C. The QTOFMS instrument was operated in electrospray ionization in positive mode with the follow-
ing parameters: curtain gas, 35 psi; ion source gas 1, 50 psi; ion source gas 2, 50 psi; temperature, 300°C; 
ion spray voltage floating, 4.5 kV; declustering potential, 100 V; acquisition speed, 2 spectra/s. For data 
processing MZmine 2 (37) and MultiQuant (SCIEX) software programs were used.
Quantification of  TML, TMAO, TMA, lysine, butyrobetaine, and carnitine. Stable-isotope-dilution LC-MS/
MS was used for quantification of TML, TMAO, TMA, lysine, γ-butyrobetaine, and carnitine similar to that 
described previously (1, 8, 9, 15). For TML standard curves, varying levels of TML were spiked into 20 μl con-
trol plasma followed by precipitation with 80 μl methanol containing 0.8 nmol d9-TML. Supernatant was load-
ed for LC-MS/MS analysis. Analyses were performed using electrospray ionization in positive-ion mode with 
multiple reaction monitoring of parent and characteristic daughter ions and retention times specific for compo-
nents monitored. The transitions monitored for TML were  m/z 189.1→84.1, 189.1→60.1, and 189.1→130.1. 
The internal standards (i.e., d9-trimethyl-TML, d9-trimethyl-TMAO) were added to plasma before protein pre-
cipitation. Various concentrations of analytes and a fixed amount of internal standards were spiked into control 
plasma to prepare the calibration curves for quantification of plasma analytes. Their concentrations in human 
and mouse plasma samples were determined by HPLC with a Shimadzu 8050 triple-quadrupole mass spectrom-
eter interfaced to a Shimadzu Nexera ultra high performance liquid chromatography (UHPLC) system.
Genotyping and imputation. Genome-wide genotyping was carried out on 3031 GeneBank subjects of  
European ancestry using the Affymetrix Genome-Wide Human Array 6.0 SNP chip. After conversion of  
genomic coordinates to GRCh37/hg19, exclusion of  SNPs with duplicates, call rates < 97%, MAFs < 1%, 
and without chromosome and base pair position, and exclusion of  44 subjects with genotype call rates < 90%, 
642,766 were available for imputation in 2,972 participants. Imputation was carried out on the forward (+) 
strand using the University of  Michigan Imputation Server (https://imputationserver.sph.umich.edu) and 
data from the 1000 Genomes Project (Phase 3, Version 5). Application of  the same quality control filters 
described above to the 46,180,700 imputed SNPs, with the addition of  excluding SNPs with Hardy-Weinberg 
equilibrium P values < 0.0001 and imputation Rsq scores < 0.3, resulted in 9,012,028 autosomal SNPs that 
were available for analysis in 1,297 GeneBank subjects for whom plasma TML levels were also available.
Total TML, carnitine, and choline quantification in food. Plant- and animal-derived products were purchased 
in various local supermarkets. A portion of  samples was accurately weighed into a 2.0-ml polypropylene 
Eppendorf  tube in a total of  1.5 ml water (if  homogenization was needed). Tissues were homogenized using 
a TissueLyser II (Qiagen) with a 5-mm stainless steel ball and with the adapters (pre-chilled at –20°C) oper-
ated at 30 Hz for 2 minutes, 5 to 10 times (until samples appeared homogeneous). After thorough mixing, a 
20-μl aliquot of  homogenate was transferred to a baked glass test tube with mininert valve screw cap, TML, 
carnitine, and choline isotope-labeled internal standards were added, and 0.5 ml 6N HCl was added. Sam-
ples were hydrolyzed by incubation under argon atmosphere at 110°C for 20 hours. Samples and standards 
were cooled down, 2 ml water added to the hydrolysate, and then the mixture was processed using solid-
phase extraction (Discovery DSC-SCX 3 ml Tube, 500 mg, Supelco). Activation and conditioning of  the 
solid-phase column before sample addition consisted of  two 2.5-ml aliquots of  methanol followed by two 
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2.5-ml aliquots of  0.2N formic acid. The sample was then loaded and subsequently washed with two 2.5-ml 
aliquots of  formic acid. Analytes were eluted using 70% methanol, 5% ammonium hydroxide, and 0.1 M 
ammonium formate. The eluent was evaporated using a heated nitrogen evaporation system, and continued 
drying of  recovered material using speed-vacuum, and then the sample was reconstituted to 100 μl with 50% 
aqueous methanol for stable-isotope-dilution LC-MS/MS analysis. Total plasma TML content of  samples 
followed a similar overall solid protocol except for the use of  d9(trimethyl)-TML as internal standard.
Metabolic challenges in mice. Whole blood (50 μl) was collected via the saphenous vein from C57BL/6J 
(Jackson Laboratory, 0664) female mice prior to gavage for the measurement of baseline analyte levels. Mice 
were administered an oral dose of stable-isotope-labeled TML or choline. The gastric gavage consisted of  
150 μl of  either 150 mM synthetic d9-TML or 150 mM choline-N,N,N-trimethyl-d9 (d9-choline, Cambridge 
Isotope Lab), followed by postgavage blood collection at the indicated times. Where indicated, gut microbiota 
were suppressed in mice by placement of a cocktail of poorly absorbed antibiotics in drinking water for 3 weeks 
prior to the d9-TML challenge, as previously described (1, 19). Quantification of the abundance of native and 
isotope-labeled forms of TML, TMA, and TMAO in mouse plasma was performed using stable-isotope-dilu-
tion LC-MS/MS using established methods for TMA and TML (19), and using the parent daughter ion transi-
tions for TML and its internal standard as described above. In additional studies, the role of gut microbiota 
in TMAO formation from dietary TML was determined in C57BL/6J mice by performance of oral (gavage) 
d9-TML challenge. Mice were housed in conventional cages in the absence or presence of a cocktail of  broad-
spectrum antibiotics added to the drinking water previously shown to suppress gut microbiota (1, 19).
Gut microbial TMA lyase activity assay. TMA lyase activity was monitored by quantifying d9-TMA produc-
tion from d9(trimethyl)-labeled potential nutrient precursors by stable-isotope-dilution LC-MS/MS analysis. 
Briefly, TMA lyase activity was typically quantified by incubating the indicated enzyme source (C57BL/6J 
female mouse intestine segments or human feces from healthy vegans/vegetarians and omnivores). Reac-
tions were initiated by the addition of  d9-labeled substrates (d9-TML, d9-carnitine, or d9-choline) incubated 
under anaerobic conditions. Following 20 hours incubation at 37°C, reactions were halted, [13C3,
15N]-TMA 
(Sigma-Aldrich) in 0.2N formic acid was added as an internal standard, followed by immediate extraction 
of  TMA isotopologues into the organic layer produced following mixing with successive additions of  2 ml 
hexane, 1 ml butanol, and 0.2 ml 1N NaOH (to deprotonate the TMA isotopologues). Mixtures were then 
vortexed, centrifuged, and the upper hexane layer was transferred to a 12 × 75 mm PTFE capped threaded 
glass tube, acidified with the addition of  200 μl of  0.2N formic acid, vortexed, and the organic and aqueous 
layers were separated by centrifugation. The now protonated TMA isotopologues were recovered in the aque-
ous phase for quantification by stable-isotope-dilution LC-MS/MS analysis. Sample aliquots were injected 
onto a reverse phase C18 HPLC column (2.0 × 150 mm, 5 μm, Phenomenex Prodigy) eluted at a flow rate 
of  0.2 ml/min and resolved using a linear gradient between 0.2% formic acid in water and 0.2% formic acid 
in acetonitrile/methanol (95:5, v/v). HPLC column effluent was introduced into an AB Sciex 5500 QTRAP 
mass spectrometer using electrospray ionization in the positive-ion mode. Both d9-TMA and [13C3,
15N]-TMA 
were monitored using multiple reaction monitoring of  parent and characteristic daughter ions: m/z 69→49 
for d9-TMA; and m/z 64→47 for [13C3,
15N]-TMA. Reactions without microbial enzyme source (tissues, cells, 
cell lysates, or isolated proteins) were used as blank. Control studies for each d9-TMA–containing substrate 
showed negligible (~0.25 nM) background d9-TMA production under the conditions employed.
In vitro screening for the conversion of  d9-TML by human commensals. Human feces and all bacteria includ-
ing individual strain and fresh combined 68 strains were grown with 100 μM d9-TML or d9-choline (as a 
positive control) in complex reduced medium in a Coy anaerobic chamber (5% H2, 20% CO2, and 75% N2, 
37°C) for 0–4 days as previously described (27). The reaction was stopped by adding 6N HCl to samples 
(1:100 dilution to 60 mM final), and freezing at –80°C until d9-TMA extraction and analysis by LC-MS/
MS, as described above in Methods.
In vivo carotid artery thrombosis model. Conventional mice (female, 10 weeks old, C57BL/6J, 10 per treat-
ment group) were placed on chemically defined diets for 11 days. Mice were assessed for in vivo thrombosis 
potential with the common carotid injury model by application of 10% FeCl3 for 1 minute (11, 38). To test this, 
platelets were labeled with rhodamine 6G (100 μl; 1 mg/ml) and injected directly into the right jugular vein. 
The left carotid artery was exposed and injured by placing a FeCl3-soaked filter paper for 1 minute. Thrombus 
formation was observed in real time and captured with a video camera linked to an intravital fluorescence 
microscope. Time to cessation of blood flow was determined by visual inspection of computer images of the 
thrombotic process from 30 seconds to 30 minutes by investigators blinded to mouse treatment group.
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Statistics. Student’s t test (2 tailed) or Wilcoxon’s rank-sum test for continuous variables and χ2 test for cat-
egorical variables were used to examine the differences between groups. Numerical data are presented as mean 
± SD or median (25th–75th percentile = Q1–Q3). Categorical data are presented as n (%). HR for MACE 
and death at 5-year follow-up and corresponding 95% CI were estimated using both univariable (unadjusted) 
and multivariable (adjusted) Cox models. Kaplan–Meier analysis with Cox proportional hazards regression was 
used for time-to-event analysis to determine HR and 95% 95% CI for MACE, and all-cause mortality. Adjust-
ments were made for individual traditional cardiac risk factors including but not limited to age, sex, HDL, LDL, 
smoking, diabetes mellitus, history of hypertension, and high-sensitivity C-reactive protein level. All analyses 
were performed using R 3.4.1 (Vienna, Austria, 2017). P values < 0.05 were considered statistically significant.
A GWAS for plasma TML levels was carried out using linear regression analyses with natural-log-
transformed values and adjustment for age and sex. All analyses were performed using PLINK 1.07 (39) 
assuming additive genetic models. The results of  the Coronary Artery Disease Genome-wide Replication 
and Meta-Analysis (CARDIoGRAM) Consortium were used to determine whether variants identified for 
plasma TML levels were associated with CVD. CARDIoGRAM represents a GWAS meta-analysis of  
CVD comprising 60,801 cases and 123,504 controls from 48 studies, in which logistic regression was first 
used in each cohort to test for association with CVD using a log-additive model with adjustment for age 
and sex and taking into account the uncertainty of  possibly imputed genotypes. Subsequently, a meta-
analysis was performed separately for every SNP from each study that passed the quality-control criteria 
using a fixed-effects model with inverse-variance weighting or a random-effects model, depending on the 
presence of  heterogeneity between studies (25). The results of  these meta-analyses were used to determine 
whether loci for TML were associated with CVD.
Study approval. All clinical study protocols and informed consent for human subjects were approved by the 
Cleveland Clinic Institutional Review Board. Written informed consent was obtained from all subjects. All ani-
mal model studies were approved by the Institutional Animal Care and Use Committee at the Cleveland Clinic.
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